| Dr Sheldon I Levin, MD | |
|
77 W Forest Ave, Suite 207, Flagstaff, AZ 86001-1479 | |
| (928) 773-2505 | |
| (928) 773-2504 |
| Full Name | Dr Sheldon I Levin |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 77 W Forest Ave, Flagstaff, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407836786 | NPI | - | NPPES |
| 889203 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 35-05-1476L (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sheldon I Levin, MD 77 W Forest Ave, Suite 207, Flagstaff, AZ 86001-1479 Ph: (928) 773-2505 | Dr Sheldon I Levin, MD 77 W Forest Ave, Suite 207, Flagstaff, AZ 86001-1479 Ph: (928) 773-2505 |
News Archive
Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has issued Notices of Allowance for three patent applications from the company's exclusively held Tuschl II patent estate.
The new generation of incretin-based medicines will allow a coordinated action against the combination diabetes/obesity, also known as diabesity, in some cases with only a single weekly dose, and with the likelihood of additional beneficial effects on other health complications related to this condition, such as cardiovascular and neurodegenerative diseases.
Researchers have discovered a way to better predict progression of Alzheimer's disease. By imaging microglial activation levels with positron emission tomography, researchers were able to better predict progression of the disease than with beta-amyloid PET imaging, according to a study published in the April issue of the Journal of Nuclear Medicine.
› Verified 3 days ago
Dr. Jeremy Nielsen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1200 N Beaver St, Flagstaff, AZ 86001 Phone: 928-779-3366 | |
Dr. Judith Amanda Kelley, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1020 N San Francisco St, Ste 100, Flagstaff, AZ 86001 Phone: 928-214-2156 | |
Kyle Richardson, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1200 N Beaver St, Flagstaff, AZ 86001 Phone: 928-779-3366 | |
Dr. Douglas Dean Lee, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 77 W Forest Ave, Suite 207, Flagstaff, AZ 86001 Phone: 928-773-2505 Fax: 928-773-2504 | |
Dr. James H Gibson, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1020 N San Francisco St, Ste 1000, Flagstaff, AZ 86001 Phone: 928-526-1112 Fax: 928-714-9285 | |
Benjamin Schumacher, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 77 W Forest Ave Ste 117, Flagstaff, AZ 86001 Phone: 928-773-2505 Fax: 928-773-2504 | |
Dr. Gary Steven Christensen, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 77 W Forest Ave, Suite 207, Flagstaff, AZ 86001 Phone: 928-773-2505 Fax: 928-773-2504 |